Jen Hsun Huang sold $38M of NVDA
President and CEO at NVIDIA CORP. 225,000 shares at an average of $169.87, traded Jul 21, 2025, filed Jul 23, 2025.
Score components
- +25RoleCEO
- +25Trade size$38.2M at market
- 0Share of holdings soldSold 0.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.2%, 3m +5.6%, 6m +7.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001197649-25-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 21, 2025 | SOpen-market sale Common Stock10b5-1 | -22,769 | $171.92 | $3.9M | 74,325,456 | Jul 23, 2025 |
| Jul 21, 2025 | SOpen-market sale Common Stock10b5-1 | -51,901 | $172.63 | $9.0M | 74,273,555 | Jul 23, 2025 |
| Jul 21, 2025 | SOpen-market sale Common Stock10b5-1 | -330 | $173.19 | $57k | 74,273,225 | Jul 23, 2025 |
| Jul 22, 2025 | SOpen-market sale Common Stock10b5-1 | -2,390 | $165.36 | $395k | 74,270,835 | Jul 23, 2025 |
| Jul 22, 2025 | SOpen-market sale Common Stock10b5-1 | -8,414 | $166.22 | $1.4M | 74,262,421 | Jul 23, 2025 |
| Jul 22, 2025 | SOpen-market sale Common Stock10b5-1 | -16,041 | $167.26 | $2.7M | 74,246,380 | Jul 23, 2025 |
| Jul 22, 2025 | SOpen-market sale Common Stock10b5-1 | -43,439 | $168.01 | $7.3M | 74,202,941 | Jul 23, 2025 |
| Jul 22, 2025 | SOpen-market sale Common Stock10b5-1 | -3,356 | $168.93 | $567k | 74,199,585 | Jul 23, 2025 |
| Jul 22, 2025 | SOpen-market sale Common Stock10b5-1 | -843 | $170.38 | $144k | 74,198,742 | Jul 23, 2025 |
| Jul 22, 2025 | SOpen-market sale Common Stock10b5-1 | -517 | $170.97 | $88k | 74,198,225 | Jul 23, 2025 |
| Jul 23, 2025 | SOpen-market sale Common Stock10b5-1 | -23,208 | $168.76 | $3.9M | 74,175,017 | Jul 23, 2025 |
| Jul 23, 2025 | SOpen-market sale Common Stock10b5-1 | -31,123 | $169.42 | $5.3M | 74,143,894 | Jul 23, 2025 |
| Jul 23, 2025 | SOpen-market sale Common Stock10b5-1 | -20,329 | $170.57 | $3.5M | 74,123,565 | Jul 23, 2025 |
| Jul 23, 2025 | SOpen-market sale Common Stock10b5-1 | -340 | $171.16 | $58k | 74,123,225 | Jul 23, 2025 |
Related signals
Other insiders at NVIDIA CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | NVIDIA CORP | Timothy S. Teter EVP, General Counsel and Sec | $6.8M 30,460 shares | -1% | |
| 75Notable | NVIDIA CORP | Mark A Stevens director | $300M 1,366,000 shares | -58% | |
| 42Moderate | NVIDIA CORP | Colette Kress EVP & Chief Financial Officer | $7.6M 34,918 shares | -4% | |
| 65Notable | NVIDIA CORP | Mark A Stevens director | $236M 1,022,239 shares | -30% | |
| 58Moderate | NVIDIA CORP | Mark A Stevens director | $411M 1,848,501 shares | -35% | |
| 28Weak | NVIDIA CORP | Timothy S. Teter EVP, General Counsel and Sec | $6.5M 30,000 shares | -1% | |
| 45Moderate | NVDAsell NVIDIA CORP | Mark A Stevens director | $186M 885,000 shares | -15% | |
| 60Notable | NVIDIA CORP | Stephen C Neal director | $3.3M 15,500 shares | -12% | |
| 60Notable | NVIDIA CORP | Mark A Stevens director | $221M 1,000,000 shares | -14% | |
| 21Weak | NVIDIA CORP | John Dabiri director | $134k 625 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.